ODDWAY INTERNATIONAL ANNOUNCES ADDITION OF POMALID TO ITS PRODUCT INVENTORY

“Pomalid 4 mg Capsules Composition of Pomalidomide, Oncology Drug by Natco Pharma Ltd”

Press Release (ePRNews.com) - New Delhi, India - Sep 19, 2017 - Oddway International, one of the largest merchants in the Wholesale Speciality Medicines, represents yet another effective medicine; Pomalid produced by Natco Pharma Ltd, which has Pomalidomide in the form of capsules, in their extensive distribution of product portfolio.

Pomalid 4 mg medicine is used to treat multiple myeloma along with other medications. Pomalidomide belongs to the class of medications known as antineoplastics which works in several ways to cause early death of the cancerous cells and to prevent uncontrolled growth of new cancer cells. Multiple myeloma is a form of blood cancer.

Oddway International has announced more than 30 categories of product catalogs and offers hundreds of high quality products at the right price in each category. They are proud of being “quality control” and “quality assurance” which provide International and Indian customers to improve health and well-being with high quality medical products.

About Oddway International

Oddway International offers a portfolio of high quality, affordable generic medicines in a variety of dosage forms and strengths including a broad range of speciality medicines. They focus on meeting the needs of pharmacies, physicians and hospitals. A vertically integrated business, economies of scale and an extremely skilled team enable them to deliver quality products in a timely manner at affordable prices. Oncology is an area of special focus. Their offered medicines are trusted by healthcare professionals in over 150 countries of the world. Their global presence is supported by 45 manufacturing facilities across 5 continents.

 

Source : Pharmaceutical Wholesale Supplier & Exporter In India

You may also like this  

DISCLAIMER : If you have any concerns regarding this press release, please contact the Author / Media Contact / Business of this press release. ePRNews is not resposible for the accuracy of the news posted and do not endorse, support any product/services/business mentioned and hereby disclaims any content contained in this press release.

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or form here

Already have an account ? Login

Reset Password

Already have an account ? Login